Meta-Analysis
Copyright ©The Author(s) 2020.
World J Cardiol. Nov 26, 2020; 12(11): 559-570
Published online Nov 26, 2020. doi: 10.4330/wjc.v12.i11.559
Table 1 Baseline characteristics of all studies
Ref.Damluji et al[12]Flores-Umanzor et al[13]Yan et al[15]Choi et al[14]
Type of studyRandomized control trial (Post Hoc analysis of BARI-2D)Cohort (prospective)Cohort (retrospective)Cohort (retrospective)
CountryUnited StatesSpainChinaSouth Korea
Period during which study was done2001-052010-142007-172003-12
Study size (Patients with DM and CTO)9725382361702
Follow up in months60484546
Male (%)78827877
Age, mean (yr)62.568.5+/-3.56064.6
Type of stent used if PCIDES or BMS-DESDES
Exclusion criteriaNeed for immediate revascularization, left main coronary disease, a creatinine level > 2.0 mg/dL, a glycated hemoglobin level > 13.0%, heart failure class III or IV, hepatic dysfunction, or previous PCI or CABG within the last 12 moNo exclusion criteria(1) Patients who had a history of CABG; (2) Patients who had acute myocardial infarction (MI) due to non-CTO vessels 1 mo before the study; (3) Patients who had left main coronary artery disease; and (4) Patients who had histories of cancer or other diseases that could confuse the end pointsHistory of previous CABG; history of cardiogenic shock or cardiopulmonary resuscitation; ST-segment elevation acute MI during the preceding 48 h
Quality score27555